The pharmaceutical company Incyte has agreed to pay $12.6 million to settle claims under  investigation by the federal government that it created a kickback scheme to increase prescriptions for an expensive blood cancer drug.

The settlement resolves a whistleblower case filed in the Eastern District of Pennsylvania and against the Wilmington, Delaware-headquartered company, accused of donating to a foundation and using those funds toward the copays of Medicare and TRICARE beneficiaries who weren’t eligible for coverage of Incyte Corp.’s drug, Jakafi.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]